KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Total Current Liabilities (2016 - 2025)

Pacific Biosciences Of California (PACB) has 16 years of Total Current Liabilities data on record, last reported at $63.2 million in Q3 2025.

  • For Q3 2025, Total Current Liabilities rose 5.35% year-over-year to $63.2 million; the TTM value through Sep 2025 reached $63.2 million, up 5.35%, while the annual FY2024 figure was $66.3 million, 30.23% down from the prior year.
  • Total Current Liabilities reached $63.2 million in Q3 2025 per PACB's latest filing, up from $59.8 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $271.4 million in Q2 2023 and bottomed at $33.7 million in Q1 2021.
  • Average Total Current Liabilities over 5 years is $104.2 million, with a median of $71.7 million recorded in 2021.
  • Peak YoY movement for Total Current Liabilities: crashed 74.44% in 2021, then soared 335.46% in 2023.
  • A 5-year view of Total Current Liabilities shows it stood at $71.7 million in 2021, then surged by 267.23% to $263.3 million in 2022, then plummeted by 63.91% to $95.0 million in 2023, then tumbled by 30.23% to $66.3 million in 2024, then fell by 4.66% to $63.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Current Liabilities were $63.2 million in Q3 2025, $59.8 million in Q2 2025, and $66.6 million in Q1 2025.